Tizanidine

Identification

Name

Tizanidine

Accession Number

DB00697  (APRD00128)

Type

Small Molecule

Groups

Approved, Investigational

Description

Tizanidine is a short-acting drug for the management of spasticity. Tizanidine is an agonist at a2-adrenergic receptor sites and presumably reduces spasticity by increasing presynaptic inhibition of motor neurons. In animal models, tizanidine has no direct effect on skeletal muscle fibers or the neuromuscular junction, and no major effect on monosynaptic spinal reflexes. The effects of tizanidine are greatest on polysynaptic pathways. The overall effect of these actions is thought to reduce facilitation of spinal motor neurons.

Structure

3D

Download

MOLSDF3D-SDFPDBSMILESInChI

Similar Structures

Structure for DB00697 (Tizanidine)

×

Close

Synonyms

• 5-Chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiadiazole
• Tizanidin
• Tizanidina
• Tizanidine
• Tizanidinum

External IDs

AN 021 / DS 103-282

Product Ingredients

Ingredient	UNII	CAS	InChI Key
Tizanidine Hydrochloride	B53E3NMY5C	64461-82-1	ZWUKMNZJRDGCTQ-UHFFFAOYSA-N

Product Images

PreviousNext

Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Tizanidine	Tablet	2 mg	Oral	Aa Pharma Inc	Not applicable	Not applicable
Tizanidine	Tablet	4 mg	Oral	Aa Pharma Inc	2004-11-17	Not applicable
Tizanidine Hydrochloride	Capsule, gelatin coated	2 mg/1	Oral	Actavis Pharma Company	2012-02-06	Not applicable
Tizanidine Hydrochloride	Capsule, gelatin coated	6 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2012-02-06	Not applicable
Tizanidine Hydrochloride	Capsule, gelatin coated	6 mg/1	Oral	Actavis Pharma Company	2012-02-06	Not applicable
Tizanidine Hydrochloride	Capsule, gelatin coated	6 mg/1	Oral	bryant ranch prepack	2012-02-06	Not applicable
Tizanidine Hydrochloride	Capsule, gelatin coated	4 mg/1	Oral	Actavis Pharma Company	2012-02-06	Not applicable
Tizanidine Hydrochloride	Capsule, gelatin coated	2 mg/1	Oral	Clinical Solutions Wholsesale	2012-02-06	2017-06-23
Zanaflex	Capsule	2 mg/1	Oral	Lake Erie Medical &Surgical Supply Dba Quality Care Products Llc	2012-03-28	2018-03-22
Zanaflex	Capsule	4 mg/1	Oral	Acorda Therapeutics	2005-04-04	Not applicable

Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Comfort Pac with Tizanidine	Kit			Pd Rx Pharmaceuticals, Inc.	2013-07-09	Not applicable
Mylan-tizanidine	Tablet	4 mg	Oral	Mylan Pharmaceuticals	2006-02-16	2017-01-09
Pal-tizanidine	Tablet	4 mg	Oral	Paladin Labs Inc	1999-10-29	Not applicable
Tizanidine	Tablet	4 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2013-04-01	Not applicable
Tizanidine	Tablet	4 mg/1	Oral	Golden State Medical Supply	2004-01-16	Not applicable
Tizanidine	Tablet	4 mg/1	Oral	Proficient Rx LP	2004-01-16	Not applicable
Tizanidine	Tablet	4 mg/1	Oral	Proficient Rx LP	2003-12-11	Not applicable
Tizanidine	Tablet	4 mg/1	Oral	A S Medication Solutions	2004-01-16	Not applicable
Tizanidine	Tablet	4 mg/1	Oral	bryant ranch prepack	2004-01-16	Not applicable
Tizanidine	Tablet	4 mg/1	Oral	Mesource Pharmaceuticals	2008-12-08	Not applicable

International/Other Brands

Cimbrar (Euroetika) / Musant (Actavis) / Myores (Meprofarm) / Navizan (Caber) / Relaxkov (Blaskov) / Sirdalid (Novartis) / Sirdalud (Novartis) / Sirdalud MR (Novartis) / Sizolan (Dr. Reddy's) / Spaslax (Panion & BF) / Telzanine (Nisshin Seiyaku) / Ternelin (Novartis) / Tizadin (ACL) / Tizaflex (Actavis) / Tizalud (Opsonin) / Tizan (Sun) / Zanpeak (Tatsumi Kagaku) / Zitanid (Novell)

Categories

• Adrenergic Agents
• Adrenergic Agonists
• Adrenergic alpha-2 Receptor Agonists
• Adrenergic alpha-Agonists
• Analgesics
• Anticonvulsants
• Autonomic Agents
• Bradycardia-Causing Agents
• Central alpha-2 Adrenergic Agonist
• Central Nervous System Agents
• Central Nervous System Depressants
• Centrally Acting Skeletal Muscle Relaxants
• Cytochrome P-450 CYP1A2 Substrates
• Hypotensive Agents
• Imidazoles
• Imidazolines
• Muscle Relaxants
• Muscle Relaxants, Central
• Muscle Relaxants, Centrally Acting Agents
• Musculo-Skeletal System
• Neuromuscular Agents
• Neurotransmitter Agents
• Parasympatholytics
• Peripheral Nervous System Agents
• Potential QTc-Prolonging Agents
• QTc Prolonging Agents
• Sensory System Agents

UNII

6AI06C00GW

CAS number

51322-75-9

Weight

Average: 253.711
Monoisotopic: 253.018893678

Chemical Formula

C₉H₈ClN₅S

InChI Key

XFYDIVBRZNQMJC-UHFFFAOYSA-N

InChI

InChI=1S/C9H8ClN5S/c10-5-1-2-6-8(15-16-14-6)7(5)13-9-11-3-4-12-9/h1-2H,3-4H2,(H2,11,12,13)

IUPAC Name

5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-2,1,3-benzothiadiazol-4-amine

SMILES

ClC1=C(NC2=NCCN2)C2=NSN=C2C=C1

Pharmacology

Indication

For the management of increased muscle tone associated with spasticity

Associated Conditions

• Acute Low Back Pain
• Muscle Spasticity
• Acute Myofascial low back pain

Pharmacodynamics

Tizanidine is a short-acting drug for the management of spasticity. Tizanidine is an agonist at a2-adrenergic receptor sites and presumably reduces spasticity by increasing presynaptic inhibition of motor neurons. In animal models, tizanidine has no direct effect on skeletal muscle fibers or the neuromuscular junction, and no major effect on monosynaptic spinal reflexes. The effects of tizanidine are greatest on polysynaptic pathways. The overall effect of these actions is thought to reduce facilitation of spinal motor neurons.

Mechanism of action

Tizanidine reduces spasticity by increasing presynaptic inhibition of motor neurons through agonist action at a2-adrenergic receptor sites.

Target	Actions	Organism
UAlpha-2A adrenergic receptor	agonist	Human
AAlpha-2B adrenergic receptor	agonist	Human
AAlpha-2C adrenergic receptor	agonist	Human
NNischarin	agonist	Human

Absorption

Not Available

Volume of distribution

• 2.4 L/kg

Protein binding

30%

Metabolism

• Tizanidine
  5-chloro-4-(guanidino)-2,1,3-benzothiadiazole
• Tizanidine
  5-chloro-4-(2-imidazolin-4-on-2-ylamino)-2,1,3-benzothiadiazole
• Tizanidine
  2-[(5-chloro-2,1,3-benzothiadiazol-4-yl)amino]-4,5-dihydro-1H-imidazol-4-ol

Route of elimination

Approximately 95% of an administered dose is metabolized.

Half life

2.5 hours

Clearance

Not Available

Toxicity

Not Available

Affected organisms

• Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
7-Nitroindazole	The risk or severity of adverse effects can be increased when Tizanidine is combined with 7-Nitroindazole.	Experimental
Abiraterone	The serum concentration of Tizanidine can be increased when it is combined with Abiraterone.	Approved
Acebutolol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Acebutolol.	Approved, Investigational
Acepromazine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Acepromazine.	Approved, Vet Approved
Aceprometazine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Aceprometazine.	Approved
Acyclovir	The serum concentration of Tizanidine can be increased when it is combined with Acyclovir.	Approved
Adipiplon	The risk or severity of adverse effects can be increased when Tizanidine is combined with Adipiplon.	Investigational
Agomelatine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Agomelatine.	Approved, Investigational
Alaproclate	The risk or severity of adverse effects can be increased when Tizanidine is combined with Alaproclate.	Experimental
Aldesleukin	The risk or severity of adverse effects can be increased when Aldesleukin is combined with Tizanidine.	Approved
Alfaxalone	The risk or severity of adverse effects can be increased when Tizanidine is combined with Alfaxalone.	Vet Approved
Alfentanil	The risk or severity of adverse effects can be increased when Alfentanil is combined with Tizanidine.	Approved, Illicit
Alfuzosin	Alfuzosin may decrease the vasoconstricting activities of Tizanidine.	Approved, Investigational
Aliskiren	The risk or severity of adverse effects can be increased when Tizanidine is combined with Aliskiren.	Approved, Investigational
Allopregnanolone	The risk or severity of adverse effects can be increased when Tizanidine is combined with Allopregnanolone.	Investigational
Alphacetylmethadol	The risk or severity of adverse effects can be increased when Tizanidine is combined with Alphacetylmethadol.	Experimental, Illicit
Alphaprodine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Alphaprodine.	Illicit
Alprazolam	The risk or severity of adverse effects can be increased when Alprazolam is combined with Tizanidine.	Approved, Illicit, Investigational
Alprenolol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Alprenolol.	Approved, Withdrawn
Amifostine	The risk or severity of adverse effects can be increased when Amifostine is combined with Tizanidine.	Approved, Investigational
Amiloride	The risk or severity of adverse effects can be increased when Amiloride is combined with Tizanidine.	Approved
Amineptine	Amineptine may decrease the antihypertensive activities of Tizanidine.	Illicit, Withdrawn
Aminophylline	The serum concentration of Tizanidine can be increased when it is combined with Aminophylline.	Approved
Amiodarone	The serum concentration of Tizanidine can be increased when it is combined with Amiodarone.	Approved, Investigational
Amisulpride	The risk or severity of adverse effects can be increased when Tizanidine is combined with Amisulpride.	Approved, Investigational
Amitriptyline	The serum concentration of Tizanidine can be increased when it is combined with Amitriptyline.	Approved
Amitriptylinoxide	Amitriptylinoxide may decrease the antihypertensive activities of Tizanidine.	Approved, Investigational
Amlodipine	The serum concentration of Tizanidine can be increased when it is combined with Amlodipine.	Approved
Amobarbital	The risk or severity of adverse effects can be increased when Amobarbital is combined with Tizanidine.	Approved, Illicit
Amoxapine	Amoxapine may decrease the antihypertensive activities of Tizanidine.	Approved
Amperozide	The risk or severity of adverse effects can be increased when Tizanidine is combined with Amperozide.	Experimental
Amphotericin B	The risk or severity of adverse effects can be increased when Amphotericin B is combined with Tizanidine.	Approved, Investigational
Amyl Nitrite	The risk or severity of adverse effects can be increased when Tizanidine is combined with Amyl Nitrite.	Approved
Anagrelide	Tizanidine may increase the QTc-prolonging activities of Anagrelide.	Approved
Anastrozole	The serum concentration of Tizanidine can be increased when it is combined with Anastrozole.	Approved, Investigational
Apomorphine	The serum concentration of Tizanidine can be increased when it is combined with Apomorphine.	Approved, Investigational
Apraclonidine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Apraclonidine.	Approved
Aripiprazole	Aripiprazole may increase the hypotensive activities of Tizanidine.	Approved, Investigational
Arotinolol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Arotinolol.	Investigational
Arsenic trioxide	Tizanidine may increase the QTc-prolonging activities of Arsenic trioxide.	Approved, Investigational
Artemether	Tizanidine may increase the QTc-prolonging activities of Artemether.	Approved
Artenimol	The serum concentration of Tizanidine can be increased when it is combined with Artenimol.	Approved, Investigational
Articaine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Articaine.	Approved
Asenapine	Tizanidine may increase the QTc-prolonging activities of Asenapine.	Approved
Atazanavir	The serum concentration of Tizanidine can be increased when it is combined with Atazanavir.	Approved, Investigational
Atenolol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Atenolol.	Approved
Azaperone	The risk or severity of adverse effects can be increased when Tizanidine is combined with Azaperone.	Investigational, Vet Approved
Azelastine	Tizanidine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.	Approved
Azilsartan medoxomil	The risk or severity of adverse effects can be increased when Tizanidine is combined with Azilsartan medoxomil.	Approved, Investigational
Azithromycin	The serum concentration of Tizanidine can be increased when it is combined with Azithromycin.	Approved
Baclofen	The risk or severity of adverse effects can be increased when Baclofen is combined with Tizanidine.	Approved
Barbexaclone	Barbexaclone may increase the hypotensive activities of Tizanidine.	Experimental
Barbital	The risk or severity of adverse effects can be increased when Tizanidine is combined with Barbital.	Illicit
Barnidipine	The risk or severity of adverse effects can be increased when Barnidipine is combined with Tizanidine.	Approved
Bedaquiline	Tizanidine may increase the QTc-prolonging activities of Bedaquiline.	Approved
Befunolol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Befunolol.	Experimental
Benazepril	The risk or severity of hypotension can be increased when Tizanidine is combined with Benazepril.	Approved, Investigational
Bendroflumethiazide	The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Tizanidine.	Approved
Benperidol	The risk or severity of adverse effects can be increased when Tizanidine is combined with Benperidol.	Approved, Investigational
Benzocaine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Benzocaine.	Approved, Investigational
Benzyl alcohol	The risk or severity of adverse effects can be increased when Tizanidine is combined with Benzyl alcohol.	Approved
Benzylpenicilloyl Polylysine	Tizanidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.	Approved
Bepridil	The risk or severity of adverse effects can be increased when Bepridil is combined with Tizanidine.	Approved, Withdrawn
Beractant	Tizanidine may increase the bradycardic activities of Beractant.	Approved
Betaxolol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Betaxolol.	Approved, Investigational
Bevantolol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Bevantolol.	Approved
Bisoprolol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.	Approved
Bopindolol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Bopindolol.	Approved
Bortezomib	The serum concentration of Tizanidine can be increased when it is combined with Bortezomib.	Approved, Investigational
Bretylium	Bretylium may increase the bradycardic activities of Tizanidine.	Approved
Brexpiprazole	The risk or severity of adverse effects can be increased when Tizanidine is combined with Brexpiprazole.	Approved, Investigational
Brimonidine	Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.	Approved
Bromazepam	The risk or severity of adverse effects can be increased when Bromazepam is combined with Tizanidine.	Approved, Illicit, Investigational
Bromisoval	The risk or severity of adverse effects can be increased when Tizanidine is combined with Bromisoval.	Experimental
Bromocriptine	The serum concentration of Tizanidine can be increased when it is combined with Bromocriptine.	Approved, Investigational
Bromperidol	The risk or severity of adverse effects can be increased when Tizanidine is combined with Bromperidol.	Approved, Investigational
Brompheniramine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Brompheniramine.	Approved
Brotizolam	The risk or severity of adverse effects can be increased when Tizanidine is combined with Brotizolam.	Approved, Investigational, Withdrawn
Bucindolol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Bucindolol.	Investigational
Bufuralol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Bufuralol.	Experimental, Investigational
Bumetanide	The risk or severity of adverse effects can be increased when Tizanidine is combined with Bumetanide.	Approved
Bunazosin	Bunazosin may decrease the vasoconstricting activities of Tizanidine.	Investigational
Bupivacaine	The risk or severity of adverse effects can be increased when Bupivacaine is combined with Tizanidine.	Approved, Investigational
Bupranolol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Bupranolol.	Approved
Buprenorphine	The serum concentration of Tizanidine can be increased when it is combined with Buprenorphine.	Approved, Illicit, Investigational, Vet Approved
Buspirone	The risk or severity of adverse effects can be increased when Buspirone is combined with Tizanidine.	Approved, Investigational
Butabarbital	The risk or severity of adverse effects can be increased when Butabarbital is combined with Tizanidine.	Approved, Illicit
Butacaine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Butacaine.	Vet Approved
Butalbital	The risk or severity of adverse effects can be increased when Butalbital is combined with Tizanidine.	Approved, Illicit
Butamben	The risk or severity of adverse effects can be increased when Tizanidine is combined with Butamben.	Approved, Withdrawn
Butethal	The risk or severity of adverse effects can be increased when Tizanidine is combined with Butethal.	Approved, Illicit
Butorphanol	The risk or severity of adverse effects can be increased when Butorphanol is combined with Tizanidine.	Approved, Illicit, Vet Approved
Butriptyline	Butriptyline may decrease the antihypertensive activities of Tizanidine.	Approved
Cabergoline	Cabergoline may increase the hypertensive and vasoconstricting activities of Tizanidine.	Approved
Caffeine	The serum concentration of Tizanidine can be increased when it is combined with Caffeine.	Approved
Calfactant	Tizanidine may increase the bradycardic activities of Calfactant.	Approved
Canagliflozin	The risk or severity of adverse effects can be increased when Tizanidine is combined with Canagliflozin.	Approved
Candesartan cilexetil	The risk or severity of adverse effects can be increased when Tizanidine is combined with Candesartan cilexetil.	Approved
Candoxatril	The risk or severity of hypotension can be increased when Tizanidine is combined with Candoxatril.	Experimental
Canertinib	The risk or severity of adverse effects can be increased when Tizanidine is combined with Canertinib.	Investigational
Captopril	The risk or severity of hypotension can be increased when Tizanidine is combined with Captopril.	Approved
Carbamazepine	The risk or severity of adverse effects can be increased when Carbamazepine is combined with Tizanidine.	Approved, Investigational
Carbetocin	The risk or severity of adverse effects can be increased when Carbetocin is combined with Tizanidine.	Approved, Investigational
Carbimazole	The serum concentration of Tizanidine can be increased when it is combined with Carbimazole.	Approved, Investigational
Carbinoxamine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Carbinoxamine.	Approved
Carfentanil	The risk or severity of adverse effects can be increased when Tizanidine is combined with Carfentanil.	Illicit, Investigational, Vet Approved
Carisoprodol	The risk or severity of adverse effects can be increased when Carisoprodol is combined with Tizanidine.	Approved
Carteolol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Carteolol.	Approved
Carvedilol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Carvedilol.	Approved, Investigational
Celiprolol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Celiprolol.	Approved, Investigational
Ceritinib	Tizanidine may increase the bradycardic activities of Ceritinib.	Approved
Cetirizine	The risk or severity of adverse effects can be increased when Cetirizine is combined with Tizanidine.	Approved
Chloral hydrate	The risk or severity of adverse effects can be increased when Tizanidine is combined with Chloral hydrate.	Approved, Illicit, Investigational, Vet Approved
Chlordiazepoxide	The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Tizanidine.	Approved, Illicit, Investigational
Chlormezanone	The risk or severity of adverse effects can be increased when Tizanidine is combined with Chlormezanone.	Approved, Investigational, Withdrawn
Chloroprocaine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Chloroprocaine.	Approved
Chloroquine	Tizanidine may increase the QTc-prolonging activities of Chloroquine.	Approved, Investigational, Vet Approved
Chlorothiazide	The risk or severity of adverse effects can be increased when Tizanidine is combined with Chlorothiazide.	Approved, Vet Approved
Chlorphenamine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Chlorphenamine.	Approved
Chlorpromazine	Tizanidine may increase the QTc-prolonging activities of Chlorpromazine.	Approved, Investigational, Vet Approved
Chlorprothixene	The risk or severity of adverse effects can be increased when Tizanidine is combined with Chlorprothixene.	Approved, Investigational, Withdrawn
Chlorthalidone	The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Tizanidine.	Approved
Chlorzoxazone	The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Tizanidine.	Approved
Cilazapril	The risk or severity of hypotension can be increased when Tizanidine is combined with Cilazapril.	Approved
Cilnidipine	The risk or severity of adverse effects can be increased when Cilnidipine is combined with Tizanidine.	Approved, Investigational
Cimetidine	The serum concentration of Tizanidine can be increased when it is combined with Cimetidine.	Approved, Investigational
Cinchocaine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Cinchocaine.	Approved, Vet Approved
Ciprofloxacin	Tizanidine may increase the QTc-prolonging activities of Ciprofloxacin.	Approved, Investigational
Cisapride	Tizanidine may increase the QTc-prolonging activities of Cisapride.	Approved, Investigational, Withdrawn
Citalopram	The serum concentration of Tizanidine can be increased when it is combined with Citalopram.	Approved
Clarithromycin	The serum concentration of Tizanidine can be increased when it is combined with Clarithromycin.	Approved
Clemastine	The risk or severity of adverse effects can be increased when Clemastine is combined with Tizanidine.	Approved, Investigational
Clevidipine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Clevidipine.	Approved, Investigational
Clidinium	The risk or severity of adverse effects can be increased when Tizanidine is combined with Clidinium.	Approved
Clobazam	The risk or severity of adverse effects can be increased when Clobazam is combined with Tizanidine.	Approved, Illicit
Clofarabine	The risk or severity of adverse effects can be increased when Clofarabine is combined with Tizanidine.	Approved, Investigational
clomethiazole	The risk or severity of adverse effects can be increased when Tizanidine is combined with clomethiazole.	Investigational
Clomipramine	Clomipramine may decrease the antihypertensive activities of Tizanidine.	Approved, Investigational, Vet Approved
Clonazepam	The risk or severity of adverse effects can be increased when Tizanidine is combined with Clonazepam.	Approved, Illicit
Clonidine	The risk or severity of adverse effects can be increased when Clonidine is combined with Tizanidine.	Approved
Clopenthixol	The risk or severity of adverse effects can be increased when Tizanidine is combined with Clopenthixol.	Experimental
Cloranolol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Cloranolol.	Experimental
Clorazepate	The risk or severity of adverse effects can be increased when Clorazepate is combined with Tizanidine.	Approved, Illicit
Clothiapine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Clothiapine.	Experimental
Clotrimazole	The serum concentration of Tizanidine can be increased when it is combined with Clotrimazole.	Approved, Vet Approved
Clozapine	The serum concentration of Tizanidine can be increased when it is combined with Clozapine.	Approved
Cocaine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Cocaine.	Approved, Illicit
Codeine	The risk or severity of adverse effects can be increased when Codeine is combined with Tizanidine.	Approved, Illicit
Conivaptan	The risk or severity of adverse effects can be increased when Conivaptan is combined with Tizanidine.	Approved, Investigational
Conjugated estrogens	The serum concentration of Tizanidine can be increased when it is combined with Conjugated estrogens.	Approved
Crisaborole	The serum concentration of Tizanidine can be increased when it is combined with Crisaborole.	Approved, Investigational
Crizotinib	Tizanidine may increase the QTc-prolonging activities of Crizotinib.	Approved
Curcumin	The serum concentration of Tizanidine can be increased when it is combined with Curcumin.	Approved, Investigational
Cyclizine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Cyclizine.	Approved
Cyclobenzaprine	The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tizanidine.	Approved
Cyclopropane	The risk or severity of adverse effects can be increased when Tizanidine is combined with Cyclopropane.	Experimental
Cyproheptadine	The risk or severity of adverse effects can be increased when Cyproheptadine is combined with Tizanidine.	Approved
Cyproterone acetate	The serum concentration of Tizanidine can be decreased when it is combined with Cyproterone acetate.	Approved, Investigational
Dantrolene	The risk or severity of adverse effects can be increased when Tizanidine is combined with Dantrolene.	Approved, Investigational
Dapagliflozin	The risk or severity of adverse effects can be increased when Tizanidine is combined with Dapagliflozin.	Approved
Dapiprazole	The risk or severity of adverse effects can be increased when Tizanidine is combined with Dapiprazole.	Approved
Dapoxetine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Dapoxetine.	Investigational
Deferasirox	The serum concentration of Tizanidine can be increased when it is combined with Deferasirox.	Approved, Investigational
Delapril	The risk or severity of hypotension can be increased when Tizanidine is combined with Delapril.	Experimental
Delavirdine	The serum concentration of Tizanidine can be increased when it is combined with Delavirdine.	Approved
Deramciclane	The risk or severity of adverse effects can be increased when Tizanidine is combined with Deramciclane.	Investigational
Desflurane	The risk or severity of adverse effects can be increased when Desflurane is combined with Tizanidine.	Approved
Desipramine	Desipramine may decrease the antihypertensive activities of Tizanidine.	Approved, Investigational
Desloratadine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Desloratadine.	Approved, Investigational
Desvenlafaxine	Desvenlafaxine may increase the tachycardic activities of Tizanidine.	Approved, Investigational
Detomidine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Detomidine.	Vet Approved
Dexbrompheniramine	The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tizanidine.	Approved
Dexmedetomidine	The serum concentration of Tizanidine can be increased when it is combined with Dexmedetomidine.	Approved, Vet Approved
Dextroamphetamine	Dextroamphetamine may decrease the vasoconstricting activities of Tizanidine.	Approved, Illicit
Dextromoramide	The risk or severity of adverse effects can be increased when Tizanidine is combined with Dextromoramide.	Experimental, Illicit
Dextropropoxyphene	The risk or severity of adverse effects can be increased when Tizanidine is combined with Dextropropoxyphene.	Approved, Illicit, Investigational, Withdrawn
Dezocine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Dezocine.	Approved, Investigational
Diazepam	The risk or severity of adverse effects can be increased when Diazepam is combined with Tizanidine.	Approved, Illicit, Investigational, Vet Approved
Dibenzepin	Dibenzepin may decrease the antihypertensive activities of Tizanidine.	Experimental
Diclofenac	The serum concentration of Tizanidine can be increased when it is combined with Diclofenac.	Approved, Vet Approved
Diclofenamide	The risk or severity of adverse effects can be increased when Tizanidine is combined with Diclofenamide.	Approved, Investigational
Diethyl ether	The risk or severity of adverse effects can be increased when Tizanidine is combined with Diethyl ether.	Experimental
Difenoxin	The risk or severity of adverse effects can be increased when Tizanidine is combined with Difenoxin.	Approved, Illicit
Digoxin	Digoxin may increase the bradycardic activities of Tizanidine.	Approved
Dihydrocodeine	The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tizanidine.	Approved, Illicit
Dihydroergotamine	Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Tizanidine.	Approved, Investigational
Dihydroetorphine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Dihydroetorphine.	Experimental, Illicit
Dihydromorphine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Dihydromorphine.	Experimental, Illicit
Diltiazem	The risk or severity of adverse effects can be increased when Diltiazem is combined with Tizanidine.	Approved, Investigational
Dimenhydrinate	The risk or severity of adverse effects can be increased when Tizanidine is combined with Dimenhydrinate.	Approved
Dimetacrine	Dimetacrine may decrease the antihypertensive activities of Tizanidine.	Approved, Withdrawn
Dinutuximab	The risk or severity of adverse effects can be increased when Tizanidine is combined with Dinutuximab.	Approved, Investigational
Diphenhydramine	The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tizanidine.	Approved, Investigational
Diphenoxylate	The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Tizanidine.	Approved, Illicit
Dipyridamole	The risk or severity of adverse effects can be increased when Tizanidine is combined with Dipyridamole.	Approved
Disopyramide	Tizanidine may increase the QTc-prolonging activities of Disopyramide.	Approved
Disulfiram	The serum concentration of Tizanidine can be increased when it is combined with Disulfiram.	Approved
Dixyrazine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Dixyrazine.	Experimental
Dofetilide	Tizanidine may increase the QTc-prolonging activities of Dofetilide.	Approved, Investigational
Dolasetron	Tizanidine may increase the QTc-prolonging activities of Dolasetron.	Approved, Investigational
Domperidone	Tizanidine may increase the QTc-prolonging activities of Domperidone.	Approved, Investigational, Vet Approved
Donepezil	Tizanidine may increase the bradycardic activities of Donepezil.	Approved
Doramectin	The risk or severity of adverse effects can be increased when Tizanidine is combined with Doramectin.	Vet Approved
Dosulepin	The serum concentration of Tizanidine can be increased when it is combined with Dosulepin.	Approved
Doxazosin	Doxazosin may decrease the vasoconstricting activities of Tizanidine.	Approved
Doxepin	Doxepin may decrease the antihypertensive activities of Tizanidine.	Approved, Investigational
Doxofylline	The serum concentration of Doxofylline can be decreased when it is combined with Tizanidine.	Approved, Investigational
Doxylamine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.	Approved, Vet Approved
DPDPE	The risk or severity of adverse effects can be increased when Tizanidine is combined with DPDPE.	Experimental
Dronabinol	Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.	Approved, Illicit
Dronedarone	Tizanidine may increase the QTc-prolonging activities of Dronedarone.	Approved
Droperidol	Droperidol may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.	Approved, Vet Approved
Drotebanol	The risk or severity of adverse effects can be increased when Tizanidine is combined with Drotebanol.	Experimental, Illicit
Duloxetine	Tizanidine may increase the orthostatic hypotensive activities of Duloxetine.	Approved
Dyclonine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Dyclonine.	Approved
Ecgonine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Ecgonine.	Experimental, Illicit
Ecopipam	The risk or severity of adverse effects can be increased when Tizanidine is combined with Ecopipam.	Investigational
Efavirenz	The risk or severity of adverse effects can be increased when Efavirenz is combined with Tizanidine.	Approved, Investigational
Efonidipine	The risk or severity of adverse effects can be increased when Efonidipine is combined with Tizanidine.	Approved, Investigational
Eliglustat	Tizanidine may increase the QTc-prolonging activities of Eliglustat.	Approved
Eltanolone	The risk or severity of adverse effects can be increased when Tizanidine is combined with Eltanolone.	Investigational
Empagliflozin	The risk or severity of adverse effects can be increased when Tizanidine is combined with Empagliflozin.	Approved
Enalapril	The risk or severity of hypotension can be increased when Tizanidine is combined with Enalapril.	Approved, Vet Approved
Enalaprilat	The risk or severity of hypotension can be increased when Tizanidine is combined with Enalaprilat.	Approved
Enflurane	The risk or severity of adverse effects can be increased when Tizanidine is combined with Enflurane.	Approved, Investigational, Vet Approved
Entacapone	The serum concentration of Tizanidine can be increased when it is combined with Entacapone.	Approved, Investigational
Epanolol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Epanolol.	Experimental
Epinephrine	Epinephrine may decrease the vasoconstricting activities of Tizanidine.	Approved, Vet Approved
Eplerenone	The risk or severity of adverse effects can be increased when Tizanidine is combined with Eplerenone.	Approved
Epoprostenol	The risk or severity of adverse effects can be increased when Epoprostenol is combined with Tizanidine.	Approved
Eprosartan	The risk or severity of adverse effects can be increased when Tizanidine is combined with Eprosartan.	Approved
Ergoloid mesylate	Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Tizanidine.	Approved
Ergonovine	Ergonovine may increase the hypertensive and vasoconstricting activities of Tizanidine.	Approved
Ergotamine	Ergotamine may increase the hypertensive and vasoconstricting activities of Tizanidine.	Approved
Erythromycin	Tizanidine may increase the QTc-prolonging activities of Erythromycin.	Approved, Investigational, Vet Approved
Esatenolol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Esatenolol.	Experimental
Escitalopram	Tizanidine may increase the QTc-prolonging activities of Escitalopram.	Approved, Investigational
Esmolol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Esmolol.	Approved
Estazolam	The risk or severity of adverse effects can be increased when Estazolam is combined with Tizanidine.	Approved, Illicit
Estradiol	The serum concentration of Tizanidine can be increased when it is combined with Estradiol.	Approved, Investigational, Vet Approved
Estradiol acetate	The serum concentration of Tizanidine can be increased when it is combined with Estradiol acetate.	Approved, Investigational, Vet Approved
Estradiol benzoate	The serum concentration of Tizanidine can be increased when it is combined with Estradiol benzoate.	Approved, Investigational, Vet Approved
Estradiol cypionate	The serum concentration of Tizanidine can be increased when it is combined with Estradiol cypionate.	Approved, Investigational, Vet Approved
Estradiol dienanthate	The serum concentration of Tizanidine can be increased when it is combined with Estradiol dienanthate.	Approved, Investigational, Vet Approved
Estradiol valerate	The serum concentration of Tizanidine can be increased when it is combined with Estradiol valerate.	Approved, Investigational, Vet Approved
Eszopiclone	The risk or severity of adverse effects can be increased when Eszopiclone is combined with Tizanidine.	Approved, Investigational
Etacrynic acid	The risk or severity of adverse effects can be increased when Tizanidine is combined with Etacrynic acid.	Approved, Investigational
Ethanol	Tizanidine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.	Approved
Ethchlorvynol	The risk or severity of adverse effects can be increased when Tizanidine is combined with Ethchlorvynol.	Approved, Illicit, Withdrawn
Ethosuximide	The risk or severity of adverse effects can be increased when Ethosuximide is combined with Tizanidine.	Approved
Ethotoin	The risk or severity of adverse effects can be increased when Tizanidine is combined with Ethotoin.	Approved
Ethyl carbamate	The risk or severity of adverse effects can be increased when Tizanidine is combined with Ethyl carbamate.	Withdrawn
Ethyl chloride	The risk or severity of adverse effects can be increased when Tizanidine is combined with Ethyl chloride.	Approved, Experimental, Investigational
Ethyl loflazepate	The risk or severity of adverse effects can be increased when Tizanidine is combined with Ethyl loflazepate.	Approved, Illicit
Ethylmorphine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Ethylmorphine.	Approved, Illicit
Etidocaine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Etidocaine.	Approved
Etifoxine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Etifoxine.	Investigational, Withdrawn
Etizolam	The risk or severity of adverse effects can be increased when Tizanidine is combined with Etizolam.	Approved
Etomidate	The risk or severity of adverse effects can be increased when Tizanidine is combined with Etomidate.	Approved
Etoperidone	The risk or severity of adverse effects can be increased when Tizanidine is combined with Etoperidone.	Withdrawn
Etorphine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Etorphine.	Illicit, Vet Approved
Ezogabine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Ezogabine.	Approved, Investigational
Felbamate	The risk or severity of adverse effects can be increased when Tizanidine is combined with Felbamate.	Approved
Felodipine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Felodipine.	Approved, Investigational
Fencamfamine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Fencamfamine.	Approved, Illicit, Withdrawn
Fenoldopam	The risk or severity of adverse effects can be increased when Fenoldopam is combined with Tizanidine.	Approved
Fentanyl	The risk or severity of adverse effects can be increased when Fentanyl is combined with Tizanidine.	Approved, Illicit, Investigational, Vet Approved
Fexofenadine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Fexofenadine.	Approved, Investigational
Fimasartan	The risk or severity of adverse effects can be increased when Fimasartan is combined with Tizanidine.	Approved, Investigational
Fingolimod	Tizanidine may increase the bradycardic activities of Fingolimod.	Approved, Investigational
Flecainide	Tizanidine may increase the QTc-prolonging activities of Flecainide.	Approved, Withdrawn
Flibanserin	The risk or severity of adverse effects can be increased when Tizanidine is combined with Flibanserin.	Approved, Investigational
Fluanisone	The risk or severity of adverse effects can be increased when Tizanidine is combined with Fluanisone.	Experimental
Fluconazole	The serum concentration of Tizanidine can be increased when it is combined with Fluconazole.	Approved, Investigational
Fludiazepam	The risk or severity of adverse effects can be increased when Tizanidine is combined with Fludiazepam.	Approved, Illicit
Flunarizine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Flunarizine.	Approved
Flunitrazepam	The risk or severity of adverse effects can be increased when Tizanidine is combined with Flunitrazepam.	Approved, Illicit
Fluoxetine	The serum concentration of Tizanidine can be increased when it is combined with Fluoxetine.	Approved, Vet Approved
Flupentixol	Tizanidine may increase the QTc-prolonging activities of Flupentixol.	Approved, Investigational, Withdrawn
Fluphenazine	The serum concentration of Tizanidine can be increased when it is combined with Fluphenazine.	Approved
Flurazepam	The risk or severity of adverse effects can be increased when Flurazepam is combined with Tizanidine.	Approved, Illicit, Investigational
Fluspirilene	The risk or severity of adverse effects can be increased when Tizanidine is combined with Fluspirilene.	Approved, Investigational
Flutamide	The serum concentration of Tizanidine can be increased when it is combined with Flutamide.	Approved, Investigational
Fluticasone propionate	The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Tizanidine.	Approved
Fluvastatin	The serum concentration of Tizanidine can be increased when it is combined with Fluvastatin.	Approved
Fluvoxamine	The serum concentration of Tizanidine can be increased when it is combined with Fluvoxamine.	Approved, Investigational
Fosinopril	The risk or severity of hypotension can be increased when Tizanidine is combined with Fosinopril.	Approved
Fosphenytoin	The risk or severity of adverse effects can be increased when Tizanidine is combined with Fosphenytoin.	Approved, Investigational
Fospropofol	The risk or severity of adverse effects can be increased when Tizanidine is combined with Fospropofol.	Approved, Illicit, Investigational
Furosemide	The risk or severity of adverse effects can be increased when Furosemide is combined with Tizanidine.	Approved, Vet Approved
Gabapentin	The risk or severity of adverse effects can be increased when Gabapentin is combined with Tizanidine.	Approved, Investigational
Gabapentin Enacarbil	The risk or severity of adverse effects can be increased when Tizanidine is combined with Gabapentin Enacarbil.	Approved, Investigational
Gadobenic acid	Tizanidine may increase the QTc-prolonging activities of Gadobenic acid.	Approved, Investigational
Galantamine	Galantamine may increase the bradycardic activities of Tizanidine.	Approved
Gamma Hydroxybutyric Acid	The risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Tizanidine.	Approved, Illicit, Investigational
Gemifloxacin	Tizanidine may increase the QTc-prolonging activities of Gemifloxacin.	Approved, Investigational
Gepirone	The risk or severity of adverse effects can be increased when Tizanidine is combined with Gepirone.	Investigational
Glecaprevir	The serum concentration of Tizanidine can be increased when it is combined with Glecaprevir.	Approved, Investigational
Glutethimide	The risk or severity of adverse effects can be increased when Tizanidine is combined with Glutethimide.	Approved, Illicit
Glycerol Phenylbutyrate	The serum concentration of Tizanidine can be increased when it is combined with Glycerol Phenylbutyrate.	Approved
Goserelin	Tizanidine may increase the QTc-prolonging activities of Goserelin.	Approved
Granisetron	Tizanidine may increase the QTc-prolonging activities of Granisetron.	Approved, Investigational
Guanfacine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Guanfacine.	Approved, Investigational
Halazepam	The risk or severity of adverse effects can be increased when Tizanidine is combined with Halazepam.	Approved, Illicit, Withdrawn
Haloperidol	Tizanidine may increase the QTc-prolonging activities of Haloperidol.	Approved
Halothane	The risk or severity of adverse effects can be increased when Halothane is combined with Tizanidine.	Approved, Vet Approved
Heroin	The risk or severity of adverse effects can be increased when Tizanidine is combined with Heroin.	Approved, Illicit, Investigational
Hexobarbital	The risk or severity of adverse effects can be increased when Tizanidine is combined with Hexobarbital.	Approved
Hyaluronidase	Hyaluronidase may increase the vasoconstricting activities of Tizanidine.	Approved, Investigational
Hydralazine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Hydralazine.	Approved
Hydrochlorothiazide	The risk or severity of adverse effects can be increased when Tizanidine is combined with Hydrochlorothiazide.	Approved, Vet Approved
Hydrocodone	Tizanidine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.	Approved, Illicit
Hydroflumethiazide	The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Tizanidine.	Approved, Investigational
Hydromorphone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Tizanidine.	Approved, Illicit
Hydroxyzine	Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.	Approved
Ibutilide	Tizanidine may increase the QTc-prolonging activities of Ibutilide.	Approved
Iloperidone	Tizanidine may increase the QTc-prolonging activities of Iloperidone.	Approved
Iloprost	The risk or severity of adverse effects can be increased when Iloprost is combined with Tizanidine.	Approved, Investigational
Imidapril	The risk or severity of hypotension can be increased when Tizanidine is combined with Imidapril.	Investigational
Imipramine	The serum concentration of Tizanidine can be increased when it is combined with Imipramine.	Approved
Indalpine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Indalpine.	Investigational, Withdrawn
Indapamide	The risk or severity of adverse effects can be increased when Tizanidine is combined with Indapamide.	Approved
Indenolol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Indenolol.	Withdrawn
Indiplon	The risk or severity of adverse effects can be increased when Tizanidine is combined with Indiplon.	Investigational
Indoramin	Indoramin may decrease the vasoconstricting activities of Tizanidine.	Withdrawn
Interferon Alfa-2b, Recombinant	The serum concentration of Tizanidine can be increased when it is combined with Interferon Alfa-2b, Recombinant.	Approved
Interferon gamma-1b	The serum concentration of Tizanidine can be increased when it is combined with Interferon gamma-1b.	Approved, Investigational
Iobenguane	The therapeutic efficacy of Iobenguane can be decreased when used in combination with Tizanidine.	Approved, Investigational
Iprindole	Iprindole may decrease the antihypertensive activities of Tizanidine.	Experimental
Irbesartan	The risk or severity of adverse effects can be increased when Tizanidine is combined with Irbesartan.	Approved, Investigational
Isocarboxazid	The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Tizanidine.	Approved
Isoflurane	The risk or severity of adverse effects can be increased when Isoflurane is combined with Tizanidine.	Approved, Vet Approved
Isoniazid	The serum concentration of Tizanidine can be increased when it is combined with Isoniazid.	Approved, Investigational
Isosorbide Dinitrate	The risk or severity of adverse effects can be increased when Tizanidine is combined with Isosorbide Dinitrate.	Approved, Investigational
Isosorbide Mononitrate	The risk or severity of adverse effects can be increased when Tizanidine is combined with Isosorbide Mononitrate.	Approved
Isoxsuprine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Isoxsuprine.	Approved, Withdrawn
Isradipine	The risk or severity of adverse effects can be increased when Isradipine is combined with Tizanidine.	Approved, Investigational
Ivabradine	Tizanidine may increase the bradycardic activities of Ivabradine.	Approved
Ketamine	The risk or severity of adverse effects can be increased when Ketamine is combined with Tizanidine.	Approved, Vet Approved
Ketazolam	The risk or severity of adverse effects can be increased when Tizanidine is combined with Ketazolam.	Approved
Ketobemidone	The risk or severity of adverse effects can be increased when Tizanidine is combined with Ketobemidone.	Approved, Investigational
Ketoconazole	The serum concentration of Tizanidine can be increased when it is combined with Ketoconazole.	Approved, Investigational
Labetalol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Labetalol.	Approved
Lacidipine	Tizanidine may increase the hypotensive activities of Lacidipine.	Approved, Investigational
Lacosamide	Tizanidine may increase the atrioventricular blocking (AV block) activities of Lacosamide.	Approved
Lamotrigine	The risk or severity of adverse effects can be increased when Lamotrigine is combined with Tizanidine.	Approved, Investigational
Landiolol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Landiolol.	Investigational
Lanreotide	Tizanidine may increase the bradycardic activities of Lanreotide.	Approved
Lenvatinib	Tizanidine may increase the QTc-prolonging activities of Lenvatinib.	Approved, Investigational
Lercanidipine	The risk or severity of adverse effects can be increased when Lercanidipine is combined with Tizanidine.	Approved, Investigational
Leuprolide	Tizanidine may increase the QTc-prolonging activities of Leuprolide.	Approved, Investigational
Levetiracetam	The risk or severity of adverse effects can be increased when Tizanidine is combined with Levetiracetam.	Approved, Investigational
Levobetaxolol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Levobetaxolol.	Approved, Investigational
Levobunolol	The risk or severity of adverse effects can be increased when Tizanidine is combined with Levobunolol.	Approved
Levobupivacaine	The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Tizanidine.	Approved, Investigational
Levocabastine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Levocabastine.	Approved, Investigational
Levocetirizine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Levocetirizine.	Approved
Levodopa	Tizanidine may increase the orthostatic hypotensive activities of Levodopa.	Approved
Levofloxacin	Tizanidine may increase the QTc-prolonging activities of Levofloxacin.	Approved, Investigational
Levomethadyl Acetate	The risk or severity of adverse effects can be increased when Tizanidine is combined with Levomethadyl Acetate.	Approved, Investigational
Levomilnacipran	Levomilnacipran may increase the tachycardic activities of Tizanidine.	Approved, Investigational
Levorphanol	The risk or severity of adverse effects can be increased when Levorphanol is combined with Tizanidine.	Approved
Levosimendan	The risk or severity of adverse effects can be increased when Levosimendan is combined with Tizanidine.	Approved, Investigational
Lidocaine	The serum concentration of Tizanidine can be increased when it is combined with Lidocaine.	Approved, Vet Approved
Lisdexamfetamine	Lisdexamfetamine may decrease the vasoconstricting activities of Tizanidine.	Approved, Investigational
Lisinopril	Tizanidine may increase the hypotensive activities of Lisinopril.	Approved, Investigational
Lithium	The risk or severity of adverse effects can be increased when Tizanidine is combined with Lithium.	Approved
Lobeglitazone	The serum concentration of Tizanidine can be increased when it is combined with Lobeglitazone.	Approved, Investigational
Lofentanil	The risk or severity of adverse effects can be increased when Tizanidine is combined with Lofentanil.	Illicit
Lofepramine	Lofepramine may decrease the antihypertensive activities of Tizanidine.	Experimental
Lofexidine	The therapeutic efficacy of Tizanidine can be increased when used in combination with Lofexidine.	Approved, Investigational
Lomefloxacin	The serum concentration of Tizanidine can be increased when it is combined with Lomefloxacin.	Approved, Investigational
Lopinavir	Tizanidine may increase the QTc-prolonging activities of Lopinavir.	Approved
Loprazolam	The risk or severity of adverse effects can be increased when Tizanidine is combined with Loprazolam.	Experimental
Loratadine	The risk or severity of adverse effects can be increased when Loratadine is combined with Tizanidine.	Approved, Investigational
Lorazepam	The risk or severity of adverse effects can be increased when Lorazepam is combined with Tizanidine.	Approved
Lormetazepam	The risk or severity of adverse effects can be increased when Tizanidine is combined with Lormetazepam.	Approved
Lorpiprazole	The therapeutic efficacy of Tizanidine can be increased when used in combination with Lorpiprazole.	Approved
Losartan	The serum concentration of Tizanidine can be increased when it is combined with Losartan.	Approved
Loxapine	The risk or severity of adverse effects can be increased when Loxapine is combined with Tizanidine.	Approved
Lucinactant	Tizanidine may increase the bradycardic activities of Lucinactant.	Approved, Investigational
Lumefantrine	Tizanidine may increase the QTc-prolonging activities of Lumefantrine.	Approved
Lurasidone	The risk or severity of adverse effects can be increased when Lurasidone is combined with Tizanidine.	Approved, Investigational
Magnesium sulfate	The therapeutic efficacy of Tizanidine can be increased when used in combination with Magnesium sulfate.	Approved, Investigational, Vet Approved
Manidipine	The serum concentration of Tizanidine can be increased when it is combined with Manidipine.	Approved, Investigational
Mannitol	The risk or severity of adverse effects can be increased when Tizanidine is combined with Mannitol.	Approved, Investigational
Maprotiline	The risk or severity of adverse effects can be increased when Tizanidine is combined with Maprotiline.	Approved, Investigational
Mebicar	The risk or severity of adverse effects can be increased when Tizanidine is combined with Mebicar.	Experimental
Mecamylamine	The risk or severity of adverse effects can be increased when Mecamylamine is combined with Tizanidine.	Approved, Investigational
Meclizine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Meclizine.	Approved
Medazepam	The risk or severity of adverse effects can be increased when Tizanidine is combined with Medazepam.	Experimental
Medetomidine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Medetomidine.	Vet Approved
Mefloquine	The therapeutic efficacy of Tizanidine can be decreased when used in combination with Mefloquine.	Approved, Investigational
Melatonin	The risk or severity of adverse effects can be increased when Tizanidine is combined with Melatonin.	Approved, Nutraceutical, Vet Approved
Melitracen	Melitracen may decrease the antihypertensive activities of Tizanidine.	Experimental, Investigational
Melperone	The risk or severity of adverse effects can be increased when Tizanidine is combined with Melperone.	Approved, Investigational
Mepindolol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Mepindolol.	Experimental
Mepivacaine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Mepivacaine.	Approved, Vet Approved
Meprobamate	The risk or severity of adverse effects can be increased when Meprobamate is combined with Tizanidine.	Approved, Illicit
Meptazinol	The risk or severity of adverse effects can be increased when Tizanidine is combined with Meptazinol.	Experimental
Mesoridazine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Mesoridazine.	Approved, Investigational
Mestranol	The serum concentration of Tizanidine can be increased when it is combined with Mestranol.	Approved
Metaxalone	The risk or severity of adverse effects can be increased when Metaxalone is combined with Tizanidine.	Approved
Methadone	Tizanidine may increase the QTc-prolonging activities of Methadone.	Approved
Methadyl Acetate	The risk or severity of adverse effects can be increased when Tizanidine is combined with Methadyl Acetate.	Approved, Illicit
Methapyrilene	The risk or severity of adverse effects can be increased when Tizanidine is combined with Methapyrilene.	Withdrawn
Methaqualone	The risk or severity of adverse effects can be increased when Tizanidine is combined with Methaqualone.	Illicit, Withdrawn
Methazolamide	The risk or severity of adverse effects can be increased when Tizanidine is combined with Methazolamide.	Approved
Methimazole	The serum concentration of Tizanidine can be increased when it is combined with Methimazole.	Approved
Methocarbamol	The risk or severity of adverse effects can be increased when Methocarbamol is combined with Tizanidine.	Approved, Vet Approved
Methohexital	The risk or severity of adverse effects can be increased when Methohexital is combined with Tizanidine.	Approved
Methotrimeprazine	Tizanidine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.	Approved, Investigational
Methoxyflurane	The risk or severity of adverse effects can be increased when Tizanidine is combined with Methoxyflurane.	Approved, Investigational, Vet Approved
Methsuximide	The risk or severity of adverse effects can be increased when Tizanidine is combined with Methsuximide.	Approved
Methyclothiazide	The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Tizanidine.	Approved
Methyldopa	The risk or severity of adverse effects can be increased when Tizanidine is combined with Methyldopa.	Approved
Methylecgonine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Methylecgonine.	Experimental
Methylergometrine	Methylergometrine may increase the hypertensive and vasoconstricting activities of Tizanidine.	Approved
Methylphenobarbital	The risk or severity of adverse effects can be increased when Tizanidine is combined with Methylphenobarbital.	Approved
Metipranolol	The risk or severity of adverse effects can be increased when Tizanidine is combined with Metipranolol.	Approved
Metolazone	The risk or severity of adverse effects can be increased when Metolazone is combined with Tizanidine.	Approved
Metoprolol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Metoprolol.	Approved, Investigational
Metyrosine	Tizanidine may increase the sedative activities of Metyrosine.	Approved
Mexiletine	The serum concentration of Tizanidine can be increased when it is combined with Mexiletine.	Approved, Investigational
Mianserin	The therapeutic efficacy of Tizanidine can be decreased when used in combination with Mianserin.	Approved, Investigational
Midazolam	The risk or severity of adverse effects can be increased when Midazolam is combined with Tizanidine.	Approved, Illicit
Midostaurin	The serum concentration of Tizanidine can be increased when it is combined with Midostaurin.	Approved, Investigational
Mifepristone	The serum concentration of Tizanidine can be increased when it is combined with Mifepristone.	Approved, Investigational
Milnacipran	Milnacipran may increase the tachycardic activities of Tizanidine.	Approved, Investigational
Minocycline	Minocycline may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.	Approved, Investigational
Minoxidil	The risk or severity of adverse effects can be increased when Minoxidil is combined with Tizanidine.	Approved, Investigational
Mirtazapine	Mirtazapine may decrease the antihypertensive activities of Tizanidine.	Approved
Moclobemide	The serum concentration of Tizanidine can be increased when it is combined with Moclobemide.	Approved, Investigational
Moexipril	The risk or severity of hypotension can be increased when Tizanidine is combined with Moexipril.	Approved
Molindone	The risk or severity of adverse effects can be increased when Tizanidine is combined with Molindone.	Approved
Morphine	The risk or severity of adverse effects can be increased when Morphine is combined with Tizanidine.	Approved, Investigational
Moxifloxacin	Tizanidine may increase the QTc-prolonging activities of Moxifloxacin.	Approved, Investigational
Moxonidine	The risk or severity of adverse effects can be increased when Moxonidine is combined with Tizanidine.	Approved, Investigational
Nabilone	Nabilone may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.	Approved, Investigational
Nadolol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Nadolol.	Approved
Nalbuphine	The risk or severity of adverse effects can be increased when Nalbuphine is combined with Tizanidine.	Approved
Nebivolol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Nebivolol.	Approved, Investigational
Nefazodone	The serum concentration of Tizanidine can be increased when it is combined with Nefazodone.	Approved, Withdrawn
Nelfinavir	The serum concentration of Tizanidine can be increased when it is combined with Nelfinavir.	Approved
Nesiritide	The risk or severity of adverse effects can be increased when Tizanidine is combined with Nesiritide.	Approved, Investigational
Nevirapine	The serum concentration of Tizanidine can be increased when it is combined with Nevirapine.	Approved
Nicardipine	The risk or severity of adverse effects can be increased when Nicardipine is combined with Tizanidine.	Approved, Investigational
Nicergoline	Nicergoline may decrease the vasoconstricting activities of Tizanidine.	Approved, Investigational
Nicorandil	Nicorandil may increase the hypotensive activities of Tizanidine.	Approved, Investigational
Nifedipine	The serum concentration of Tizanidine can be increased when it is combined with Nifedipine.	Approved
Niguldipine	Niguldipine may decrease the vasoconstricting activities of Tizanidine.	Experimental
Nilotinib	Tizanidine may increase the QTc-prolonging activities of Nilotinib.	Approved, Investigational
Nilvadipine	The risk or severity of adverse effects can be increased when Nilvadipine is combined with Tizanidine.	Approved, Investigational
Nimodipine	The risk or severity of adverse effects can be increased when Nimodipine is combined with Tizanidine.	Approved, Investigational
Nisoldipine	The serum concentration of Tizanidine can be increased when it is combined with Nisoldipine.	Approved
Nitrazepam	The risk or severity of adverse effects can be increased when Nitrazepam is combined with Tizanidine.	Approved
Nitrendipine	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Tizanidine.	Approved, Investigational
Nitric Oxide	The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Tizanidine.	Approved
Nitroglycerin	The risk or severity of adverse effects can be increased when Tizanidine is combined with Nitroglycerin.	Approved, Investigational
Nitroprusside	The risk or severity of adverse effects can be increased when Nitroprusside is combined with Tizanidine.	Approved, Investigational
Nitrous acid	The risk or severity of adverse effects can be increased when Nitrous acid is combined with Tizanidine.	Approved, Investigational
Nitrous oxide	The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Tizanidine.	Approved, Vet Approved
Nordazepam	The risk or severity of adverse effects can be increased when Tizanidine is combined with Nordazepam.	Approved
Norfloxacin	The serum concentration of Tizanidine can be increased when it is combined with Norfloxacin.	Approved
Norflurane	The risk or severity of adverse effects can be increased when Tizanidine is combined with Norflurane.	Approved, Investigational
Normethadone	The risk or severity of adverse effects can be increased when Tizanidine is combined with Normethadone.	Approved, Illicit
Nortriptyline	Nortriptyline may decrease the antihypertensive activities of Tizanidine.	Approved
Obeticholic acid	The serum concentration of Tizanidine can be increased when it is combined with Obeticholic acid.	Approved
Obinutuzumab	The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Tizanidine.	Approved, Investigational
Octreotide	Octreotide may increase the bradycardic activities of Tizanidine.	Approved, Investigational
Ofloxacin	Tizanidine may increase the QTc-prolonging activities of Ofloxacin.	Approved
Olanzapine	The serum concentration of Tizanidine can be increased when it is combined with Olanzapine.	Approved, Investigational
Olmesartan	The risk or severity of adverse effects can be increased when Olmesartan is combined with Tizanidine.	Approved, Investigational
Olopatadine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Olopatadine.	Approved
Omapatrilat	The risk or severity of hypotension can be increased when Tizanidine is combined with Omapatrilat.	Investigational
Omeprazole	The serum concentration of Tizanidine can be increased when it is combined with Omeprazole.	Approved, Investigational, Vet Approved
Ondansetron	The serum concentration of Tizanidine can be increased when it is combined with Ondansetron.	Approved
Opipramol	Opipramol may decrease the antihypertensive activities of Tizanidine.	Investigational
Opium	The risk or severity of adverse effects can be increased when Tizanidine is combined with Opium.	Approved, Illicit
Orlistat	The serum concentration of Tizanidine can be decreased when it is combined with Orlistat.	Approved, Investigational
Orphenadrine	The serum concentration of Tizanidine can be increased when it is combined with Orphenadrine.	Approved
Osanetant	The risk or severity of adverse effects can be increased when Tizanidine is combined with Osanetant.	Investigational
Osimertinib	The serum concentration of Tizanidine can be decreased when it is combined with Osimertinib.	Approved
Oxazepam	The risk or severity of adverse effects can be increased when Oxazepam is combined with Tizanidine.	Approved
Oxprenolol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.	Approved
Oxybuprocaine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Oxybuprocaine.	Approved, Investigational
Oxycodone	The risk or severity of adverse effects can be increased when Oxycodone is combined with Tizanidine.	Approved, Illicit, Investigational
Oxymorphone	The risk or severity of adverse effects can be increased when Oxymorphone is combined with Tizanidine.	Approved, Investigational, Vet Approved
Paclitaxel	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Tizanidine.	Approved, Vet Approved
Paliperidone	Tizanidine may increase the QTc-prolonging activities of Paliperidone.	Approved
Panobinostat	Tizanidine may increase the QTc-prolonging activities of Panobinostat.	Approved, Investigational
Papaverine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Papaverine.	Approved, Investigational
Paraldehyde	Tizanidine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.	Approved, Investigational
Paroxetine	The serum concentration of Tizanidine can be increased when it is combined with Paroxetine.	Approved, Investigational
Pasireotide	Tizanidine may increase the bradycardic activities of Pasireotide.	Approved
Pazopanib	Tizanidine may increase the QTc-prolonging activities of Pazopanib.	Approved
Peginterferon alfa-2a	The serum concentration of Tizanidine can be increased when it is combined with Peginterferon alfa-2a.	Approved, Investigational
Peginterferon alfa-2b	The serum concentration of Tizanidine can be increased when it is combined with Peginterferon alfa-2b.	Approved
Penbutolol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Penbutolol.	Approved, Investigational
Penfluridol	The risk or severity of adverse effects can be increased when Tizanidine is combined with Penfluridol.	Experimental
Pentamidine	Tizanidine may increase the QTc-prolonging activities of Pentamidine.	Approved, Investigational
Pentazocine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Tizanidine.	Approved, Vet Approved
Pentobarbital	The risk or severity of adverse effects can be increased when Pentobarbital is combined with Tizanidine.	Approved, Investigational, Vet Approved
Pentoxifylline	The serum concentration of Tizanidine can be increased when it is combined with Pentoxifylline.	Approved, Investigational
Perampanel	Perampanel may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.	Approved
Perazine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Perazine.	Approved, Investigational
Perflutren	Tizanidine may increase the QTc-prolonging activities of Perflutren.	Approved
Perindopril	The risk or severity of hypotension can be increased when Tizanidine is combined with Perindopril.	Approved
Perospirone	The risk or severity of adverse effects can be increased when Tizanidine is combined with Perospirone.	Approved
Perphenazine	The serum concentration of Tizanidine can be increased when it is combined with Perphenazine.	Approved
Pethidine	The risk or severity of adverse effects can be increased when Pethidine is combined with Tizanidine.	Approved
Phenazocine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Phenazocine.	Experimental
Phenelzine	The risk or severity of adverse effects can be increased when Phenelzine is combined with Tizanidine.	Approved
Phenibut	The risk or severity of adverse effects can be increased when Tizanidine is combined with Phenibut.	Experimental
Phenobarbital	The risk or severity of adverse effects can be increased when Phenobarbital is combined with Tizanidine.	Approved, Investigational
Phenoperidine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Phenoperidine.	Experimental
Phenoxybenzamine	The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Tizanidine.	Approved
Phenoxyethanol	The risk or severity of adverse effects can be increased when Tizanidine is combined with Phenoxyethanol.	Approved
Phentolamine	The risk or severity of adverse effects can be increased when Phentolamine is combined with Tizanidine.	Approved
Phenylbutyric acid	The serum concentration of Tizanidine can be increased when it is combined with Phenylbutyric acid.	Approved, Investigational
Phenytoin	The risk or severity of adverse effects can be increased when Phenytoin is combined with Tizanidine.	Approved, Vet Approved
Pibrentasvir	The serum concentration of Tizanidine can be increased when it is combined with Pibrentasvir.	Approved, Investigational
Pimozide	Tizanidine may increase the QTc-prolonging activities of Pimozide.	Approved
Pindolol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Pindolol.	Approved, Investigational
Pipamperone	The risk or severity of adverse effects can be increased when Pipamperone is combined with Tizanidine.	Approved, Investigational
Pipotiazine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Pipotiazine.	Approved, Investigational
Piritramide	The risk or severity of adverse effects can be increased when Tizanidine is combined with Piritramide.	Approved, Investigational
Pizotifen	The risk or severity of adverse effects can be increased when Tizanidine is combined with Pizotifen.	Approved
Platelet Activating Factor	Tizanidine may increase the atrioventricular blocking (AV block) activities of Platelet Activating Factor.	Experimental
Pomalidomide	The risk or severity of adverse effects can be increased when Tizanidine is combined with Pomalidomide.	Approved
Poractant alfa	Tizanidine may increase the bradycardic activities of Poractant alfa.	Approved
Practolol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Practolol.	Approved
Pramipexole	Tizanidine may increase the sedative activities of Pramipexole.	Approved, Investigational
Pramocaine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Pramocaine.	Approved
Prazepam	The risk or severity of adverse effects can be increased when Tizanidine is combined with Prazepam.	Approved, Illicit
Prazosin	Prazosin may decrease the vasoconstricting activities of Tizanidine.	Approved
Pregabalin	The therapeutic efficacy of Tizanidine can be decreased when used in combination with Pregabalin.	Approved, Illicit, Investigational
Prilocaine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Prilocaine.	Approved
Primaquine	Tizanidine may increase the QTc-prolonging activities of Primaquine.	Approved
Primidone	The risk or severity of adverse effects can be increased when Tizanidine is combined with Primidone.	Approved, Vet Approved
Procainamide	Tizanidine may increase the QTc-prolonging activities of Procainamide.	Approved
Procaine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Procaine.	Approved, Investigational, Vet Approved
Prochlorperazine	The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tizanidine.	Approved, Vet Approved
Promazine	Tizanidine may increase the QTc-prolonging activities of Promazine.	Approved, Vet Approved
Promethazine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Promethazine.	Approved, Investigational
Propafenone	The serum concentration of Tizanidine can be increased when it is combined with Propafenone.	Approved
Propanidid	The risk or severity of adverse effects can be increased when Tizanidine is combined with Propanidid.	Experimental
Proparacaine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Proparacaine.	Approved, Vet Approved
Propericiazine	Propericiazine may decrease the vasoconstricting activities of Tizanidine.	Approved, Investigational
Propiomazine	Propiomazine may decrease the vasoconstricting activities of Tizanidine.	Approved
Propiverine	Propiverine may decrease the vasoconstricting activities of Tizanidine.	Approved, Investigational
Propofol	The serum concentration of Tizanidine can be increased when it is combined with Propofol.	Approved, Investigational, Vet Approved
Propoxycaine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Propoxycaine.	Approved
Propranolol	The serum concentration of Tizanidine can be increased when it is combined with Propranolol.	Approved, Investigational
Protriptyline	Protriptyline may decrease the antihypertensive activities of Tizanidine.	Approved
Proxibarbal	The risk or severity of adverse effects can be increased when Tizanidine is combined with Proxibarbal.	Experimental
PSD502	The risk or severity of adverse effects can be increased when Tizanidine is combined with PSD502.	Investigational
Quazepam	The risk or severity of adverse effects can be increased when Quazepam is combined with Tizanidine.	Approved, Illicit
Quetiapine	Tizanidine may increase the QTc-prolonging activities of Quetiapine.	Approved
Quinapril	The risk or severity of hypotension can be increased when Tizanidine is combined with Quinapril.	Approved, Investigational
Quinidine	Tizanidine may increase the QTc-prolonging activities of Quinidine.	Approved, Investigational
Quinine	Tizanidine may increase the QTc-prolonging activities of Quinine.	Approved
Quinisocaine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Quinisocaine.	Experimental
Racepinephrine	Racepinephrine may decrease the vasoconstricting activities of Tizanidine.	Approved
Raclopride	The risk or severity of adverse effects can be increased when Tizanidine is combined with Raclopride.	Investigational
Ramelteon	The risk or severity of adverse effects can be increased when Tizanidine is combined with Ramelteon.	Approved, Investigational
Ramipril	The risk or severity of hypotension can be increased when Tizanidine is combined with Ramipril.	Approved
Ranitidine	The serum concentration of Tizanidine can be increased when it is combined with Ranitidine.	Approved
Rasagiline	The risk or severity of adverse effects can be increased when Rasagiline is combined with Tizanidine.	Approved
Remifentanil	The risk or severity of adverse effects can be increased when Remifentanil is combined with Tizanidine.	Approved
Remoxipride	The risk or severity of adverse effects can be increased when Tizanidine is combined with Remoxipride.	Approved, Withdrawn
Rescinnamine	The risk or severity of hypotension can be increased when Tizanidine is combined with Rescinnamine.	Approved
Reserpine	The risk or severity of adverse effects can be increased when Reserpine is combined with Tizanidine.	Approved, Investigational
Rhein	The serum concentration of Tizanidine can be increased when it is combined with Rhein.	Experimental
Riociguat	The risk or severity of adverse effects can be increased when Tizanidine is combined with Riociguat.	Approved
Risperidone	Tizanidine may increase the hypotensive activities of Risperidone.	Approved, Investigational
Ritanserin	The risk or severity of adverse effects can be increased when Tizanidine is combined with Ritanserin.	Investigational
Rivastigmine	Tizanidine may increase the bradycardic activities of Rivastigmine.	Approved, Investigational
Romifidine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Romifidine.	Vet Approved
Ropinirole	The serum concentration of Tizanidine can be increased when it is combined with Ropinirole.	Approved, Investigational
Ropivacaine	The risk or severity of adverse effects can be increased when Ropivacaine is combined with Tizanidine.	Approved
Rotigotine	Tizanidine may increase the sedative activities of Rotigotine.	Approved
Rucaparib	The serum concentration of Tizanidine can be increased when it is combined with Rucaparib.	Approved, Investigational
Rufinamide	The risk or severity of adverse effects can be increased when Rufinamide is combined with Tizanidine.	Approved
Ruxolitinib	Ruxolitinib may increase the bradycardic activities of Tizanidine.	Approved
Sacubitril	The risk or severity of adverse effects can be increased when Sacubitril is combined with Tizanidine.	Approved
Saquinavir	Tizanidine may increase the QTc-prolonging activities of Saquinavir.	Approved, Investigational
Scopolamine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Scopolamine.	Approved, Investigational
Secobarbital	The risk or severity of adverse effects can be increased when Secobarbital is combined with Tizanidine.	Approved, Vet Approved
Selegiline	The serum concentration of Tizanidine can be increased when it is combined with Selegiline.	Approved, Investigational, Vet Approved
Sepranolone	The risk or severity of adverse effects can be increased when Tizanidine is combined with Sepranolone.	Investigational
Sertindole	The risk or severity of adverse effects can be increased when Tizanidine is combined with Sertindole.	Approved, Investigational, Withdrawn
Sertraline	The serum concentration of Tizanidine can be increased when it is combined with Sertraline.	Approved
Sevoflurane	The risk or severity of adverse effects can be increased when Sevoflurane is combined with Tizanidine.	Approved, Vet Approved
Silodosin	Silodosin may decrease the vasoconstricting activities of Tizanidine.	Approved
Simeprevir	The serum concentration of Tizanidine can be increased when it is combined with Simeprevir.	Approved
Sodium oxybate	Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.	Approved
Sotalol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Sotalol.	Approved
Spirapril	The risk or severity of hypotension can be increased when Tizanidine is combined with Spirapril.	Approved
Spironolactone	Spironolactone may decrease the vasoconstricting activities of Tizanidine.	Approved
Stiripentol	The risk or severity of adverse effects can be increased when Tizanidine is combined with Stiripentol.	Approved
Streptokinase	The risk or severity of adverse effects can be increased when Streptokinase is combined with Tizanidine.	Approved, Investigational
Sufentanil	The risk or severity of adverse effects can be increased when Sufentanil is combined with Tizanidine.	Approved, Investigational
Sulconazole	The serum concentration of Tizanidine can be increased when it is combined with Sulconazole.	Approved
Sulfisoxazole	Tizanidine may increase the QTc-prolonging activities of Sulfisoxazole.	Approved, Vet Approved
Sulpiride	The risk or severity of adverse effects can be increased when Tizanidine is combined with Sulpiride.	Approved, Investigational
Sultopride	The risk or severity of adverse effects can be increased when Tizanidine is combined with Sultopride.	Experimental
Suvorexant	Tizanidine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.	Approved, Investigational
Synthetic Conjugated Estrogens, A	The serum concentration of Tizanidine can be increased when it is combined with Synthetic Conjugated Estrogens, A.	Approved
Talinolol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Talinolol.	Investigational
Tamsulosin	Tamsulosin may decrease the vasoconstricting activities of Tizanidine.	Approved, Investigational
Tandospirone	The risk or severity of adverse effects can be increased when Tizanidine is combined with Tandospirone.	Investigational
Tapentadol	Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.	Approved
Tasimelteon	The risk or severity of adverse effects can be increased when Tizanidine is combined with Tasimelteon.	Approved, Investigational
Telavancin	Tizanidine may increase the QTc-prolonging activities of Telavancin.	Approved
Telithromycin	Tizanidine may increase the QTc-prolonging activities of Telithromycin.	Approved
Telmisartan	The risk or severity of adverse effects can be increased when Tizanidine is combined with Telmisartan.	Approved, Investigational
Temazepam	The risk or severity of adverse effects can be increased when Temazepam is combined with Tizanidine.	Approved, Investigational
Temocapril	The risk or severity of hypotension can be increased when Tizanidine is combined with Temocapril.	Experimental, Investigational
Tenofovir disoproxil	The serum concentration of Tizanidine can be increased when it is combined with Tenofovir disoproxil.	Approved, Investigational
Terazosin	Terazosin may decrease the vasoconstricting activities of Tizanidine.	Approved
Terbutaline	Tizanidine may increase the atrioventricular blocking (AV block) activities of Terbutaline.	Approved
Teriflunomide	The serum concentration of Tizanidine can be decreased when it is combined with Teriflunomide.	Approved
Tertatolol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Tertatolol.	Experimental
Tetrabenazine	Tizanidine may increase the QTc-prolonging activities of Tetrabenazine.	Approved, Investigational
Tetracaine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Tetracaine.	Approved, Vet Approved
Tetrahydropalmatine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Tetrahydropalmatine.	Investigational
Tetrodotoxin	The risk or severity of adverse effects can be increased when Tizanidine is combined with Tetrodotoxin.	Investigational
Thalidomide	Tizanidine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.	Approved, Investigational, Withdrawn
Theophylline	The serum concentration of Tizanidine can be increased when it is combined with Theophylline.	Approved
Thiamylal	The risk or severity of adverse effects can be increased when Tizanidine is combined with Thiamylal.	Approved, Vet Approved
Thiopental	The risk or severity of adverse effects can be increased when Tizanidine is combined with Thiopental.	Approved, Vet Approved
Thioproperazine	Thioproperazine may decrease the vasoconstricting activities of Tizanidine.	Approved
Thioridazine	The serum concentration of Tizanidine can be increased when it is combined with Thioridazine.	Approved, Withdrawn
Thiothixene	The risk or severity of adverse effects can be increased when Thiothixene is combined with Tizanidine.	Approved
Tiagabine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Tiagabine.	Approved, Investigational
Tianeptine	Tianeptine may decrease the antihypertensive activities of Tizanidine.	Approved, Investigational
Tiapride	The risk or severity of adverse effects can be increased when Tizanidine is combined with Tiapride.	Approved, Investigational
Ticlopidine	The serum concentration of Tizanidine can be increased when it is combined with Ticlopidine.	Approved
Tiletamine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Tiletamine.	Vet Approved
Tilidine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Tilidine.	Experimental
Timolol	Tizanidine may increase the atrioventricular blocking (AV block) activities of Timolol.	Approved
Tioconazole	The serum concentration of Tizanidine can be increased when it is combined with Tioconazole.	Approved
Tofacitinib	Tofacitinib may increase the bradycardic activities of Tizanidine.	Approved, Investigational
Tolazoline	The risk or severity of adverse effects can be increased when Tolazoline is combined with Tizanidine.	Approved, Vet Approved
Tolcapone	The risk or severity of adverse effects can be increased when Tolcapone is combined with Tizanidine.	Approved, Withdrawn
Topiramate	The risk or severity of adverse effects can be increased when Topiramate is combined with Tizanidine.	Approved
Torasemide	The risk or severity of adverse effects can be increased when Torasemide is combined with Tizanidine.	Approved
Toremifene	Tizanidine may increase the QTc-prolonging activities of Toremifene.	Approved, Investigational
Tramadol	The risk or severity of adverse effects can be increased when Tramadol is combined with Tizanidine.	Approved, Investigational
Trandolapril	The risk or severity of hypotension can be increased when Tizanidine is combined with Trandolapril.	Approved
Tranylcypromine	The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tizanidine.	Approved, Investigational
Trazodone	The risk or severity of adverse effects can be increased when Tizanidine is combined with Trazodone.	Approved, Investigational
Tretinoin	The risk or severity of adverse effects can be increased when Tretinoin is combined with Tizanidine.	Approved, Investigational, Nutraceutical
Triamterene	The risk or severity of adverse effects can be increased when Triamterene is combined with Tizanidine.	Approved
Triazolam	The risk or severity of adverse effects can be increased when Triazolam is combined with Tizanidine.	Approved, Investigational
Tricaine methanesulfonate	The risk or severity of adverse effects can be increased when Tizanidine is combined with Tricaine methanesulfonate.	Vet Approved
Trichloroethylene	The risk or severity of adverse effects can be increased when Tizanidine is combined with Trichloroethylene.	Approved
Trifluoperazine	The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tizanidine.	Approved, Investigational
Trifluperidol	The risk or severity of adverse effects can be increased when Tizanidine is combined with Trifluperidol.	Experimental
Triflupromazine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Triflupromazine.	Approved, Vet Approved
Trimazosin	Trimazosin may decrease the vasoconstricting activities of Tizanidine.	Experimental
Trimipramine	Trimipramine may decrease the antihypertensive activities of Tizanidine.	Approved
Triprolidine	The risk or severity of adverse effects can be increased when Triprolidine is combined with Tizanidine.	Approved
Urapidil	Urapidil may decrease the vasoconstricting activities of Tizanidine.	Investigational
Valaciclovir	The serum concentration of Tizanidine can be increased when it is combined with Valaciclovir.	Approved, Investigational
Valproic Acid	The risk or severity of adverse effects can be increased when Tizanidine is combined with Valproic Acid.	Approved, Investigational
Valsartan	The risk or severity of adverse effects can be increased when Valsartan is combined with Tizanidine.	Approved, Investigational
Vandetanib	Tizanidine may increase the QTc-prolonging activities of Vandetanib.	Approved
Vemurafenib	The serum concentration of Tizanidine can be increased when it is combined with Vemurafenib.	Approved
Venlafaxine	Venlafaxine may increase the tachycardic activities of Tizanidine.	Approved
Veralipride	The risk or severity of adverse effects can be increased when Tizanidine is combined with Veralipride.	Experimental
Verapamil	The serum concentration of Tizanidine can be increased when it is combined with Verapamil.	Approved
Vigabatrin	The risk or severity of adverse effects can be increased when Tizanidine is combined with Vigabatrin.	Approved
Vinyl ether	The risk or severity of adverse effects can be increased when Tizanidine is combined with Vinyl ether.	Experimental
Vortioxetine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Vortioxetine.	Approved, Investigational
Xenon	The risk or severity of adverse effects can be increased when Tizanidine is combined with Xenon.	Experimental
Xylazine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Xylazine.	Vet Approved
Zafirlukast	The serum concentration of Tizanidine can be increased when it is combined with Zafirlukast.	Approved, Investigational
Zaleplon	The risk or severity of adverse effects can be increased when Zaleplon is combined with Tizanidine.	Approved, Illicit, Investigational
Ziconotide	The risk or severity of adverse effects can be increased when Tizanidine is combined with Ziconotide.	Approved
Zileuton	The serum concentration of Tizanidine can be increased when it is combined with Zileuton.	Approved, Investigational, Withdrawn
Zimelidine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Zimelidine.	Withdrawn
Ziprasidone	Tizanidine may increase the QTc-prolonging activities of Ziprasidone.	Approved
Zofenopril	The risk or severity of hypotension can be increased when Tizanidine is combined with Zofenopril.	Experimental
Zolazepam	The risk or severity of adverse effects can be increased when Tizanidine is combined with Zolazepam.	Vet Approved
Zolpidem	Tizanidine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.	Approved
Zonisamide	The risk or severity of adverse effects can be increased when Tizanidine is combined with Zonisamide.	Approved, Investigational
Zopiclone	The risk or severity of adverse effects can be increased when Zopiclone is combined with Tizanidine.	Approved
Zotepine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Zotepine.	Approved, Investigational, Withdrawn
Zucapsaicin	The serum concentration of Tizanidine can be increased when it is combined with Zucapsaicin.	Approved, Investigational
Zuclopenthixol	Tizanidine may increase the QTc-prolonging activities of Zuclopenthixol.	Approved, Investigational

Food Interactions

Not Available

References

Synthesis Reference

Pavel Hradil, Lubomir Kvapil, Martin Grepl, Jan Novotny, "METHOD FOR THE PREPARATION OF TIZANIDINE HYDROCHLORIDE." U.S. Patent US20110263863, issued October 27, 2011.

US20110263863

General References

Not Available

External Links

Human Metabolome Database

HMDB0060964

KEGG Compound

C07452

PubChem Compound

5487

PubChem Substance

46505373

ChemSpider

5287

BindingDB

50240671

ChEBI

63629

ChEMBL

CHEMBL1079

Therapeutic Targets Database

DAP000234

PharmGKB

PA451701

RxList

RxList Drug Page

Drugs.com

Drugs.com Drug Page

Wikipedia

Tizanidine

ATC Codes

M03BX02 — Tizanidine

• M03BX — Other centrally acting agents
• M03B — MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS
• M03 — MUSCLE RELAXANTS
• M — MUSCULO-SKELETAL SYSTEM

AHFS Codes

• 12:20.04 — Centrally Acting Skeletal Muscle Relaxants

FDA label

Download (145 KB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
1	Completed	Other	Malignant Melanoma, Neoplasms	1
1	Completed	Treatment	Healthy Volunteers	2
1	Terminated	Treatment	Spasticity Due to Cerebral Palsy	1
1, 2	Completed	Treatment	Muscle Spasticity	1
2	Completed	Treatment	Spasticity	1
2	Withdrawn	Treatment	Acute Muscle Pain	1
3	Completed	Treatment	Disseminated Sclerosis / Muscle Spasticity / Spinal Cord Injuries (SCI) / Strokes	1
3	Completed	Treatment	Low Back Pain (LBP)	1
3	Completed	Treatment	Vertebrogenic Radiculopathy L5, S1	1
4	Completed	Treatment	Thyroidectomy	1
4	Completed	Treatment	Unilateral Inguinal Hernia	1
4	Completed	Treatment	Upper Limb Spasticity	1
4	Recruiting	Treatment	Low Back Pain (LBP)	1
Not Available	Completed	Not Available	Acute Gouty Arthritis / Arthritis / Headaches / Migraines / Muscle Spasms / Radicular syndrome / Synovitis / Tendonitis	1

Pharmacoeconomics

Manufacturers

• Acorda therapeutics inc
• Actavis elizabeth llc
• Actavis totowa llc
• Alphapharm party ltd
• Apotex inc
• Barr laboratories inc
• Caraco pharmaceutical laboratories ltd
• Corepharma llc
• Dr reddys laboratories inc
• Ivax pharmaceuticals inc sub teva pharmaceuticals usa
• Mylan pharmaceuticals inc
• Sandoz inc
• Teva pharmaceuticals usa inc

Packagers

• Acorda Therapeutics
• Aidarex Pharmacuticals LLC
• Alphapharm Party Ltd.
• Altura Pharmaceuticals Inc.
• Amerisource Health Services Corp.
• Amneal Pharmaceuticals
• Apotex Inc.
• A-S Medication Solutions LLC
• Bryant Ranch Prepack
• Caraco Pharmaceutical Labs
• Cardinal Health
• Corepharma LLC
• Deca Pharmaceuticals LLC
• Dispensing Solutions
• Diversified Healthcare Services Inc.
• Doctor Reddys Laboratories Ltd.
• Elan Pharmaceuticals Inc.
• Eon Labs
• Genpharm LP
• H.J. Harkins Co. Inc.
• Heartland Repack Services LLC
• Innoviant Pharmacy Inc.
• Ivax Pharmaceuticals
• Keltman Pharmaceuticals Inc.
• Lake Erie Medical and Surgical Supply
• Major Pharmaceuticals
• Murfreesboro Pharmaceutical Nursing Supply
• Mylan
• Nucare Pharmaceuticals Inc.
• Palmetto Pharmaceuticals Inc.
• Par Pharmaceuticals
• Patheon Inc.
• PCA LLC
• PD-Rx Pharmaceuticals Inc.
• Physicians Total Care Inc.
• Preferred Pharmaceuticals Inc.
• Prepak Systems Inc.
• Rebel Distributors Corp.
• Redpharm Drug
• Resource Optimization and Innovation LLC
• Southwood Pharmaceuticals
• St Mary's Medical Park Pharmacy
• Stat Rx Usa
• Torpharm Inc.
• UDL Laboratories
• Vangard Labs Inc.

Dosage forms

Form	Route	Strength
Kit
Tablet	Oral	2 mg/1
Tablet	Oral	2 mg
Tablet	Oral	4 mg/1
Tablet	Oral	4 mg
Capsule, gelatin coated	Oral	2 mg/1
Capsule, gelatin coated	Oral	4 mg/1
Capsule, gelatin coated	Oral	6 mg/1
Capsule	Oral	2 mg/1
Capsule	Oral	4 mg/1
Capsule	Oral	6 mg/1

Prices

Unit description	Cost	Unit
Zanaflex 6 mg capsule	4.79USD	capsule
Zanaflex 4 mg capsule	3.2USD	capsule
Zanaflex 2 mg capsule	2.52USD	capsule
Zanaflex 4 mg tablet	2.29USD	tablet
Tizanidine hcl 4 mg tablet	1.49USD	tablet
Zanaflex 2 mg tablet	1.42USD	tablet
Tizanidine hcl 2 mg tablet	1.25USD	tablet

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
US6455557	No	2001-11-28	2021-11-28

Properties

State

Solid

Experimental Properties

Property	Value	Source
logP	1.4	Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.133 mg/mL	ALOGPS
logP	1.6	ALOGPS
logP	2.02	ChemAxon
logS	-3.3	ALOGPS
pKa (Strongest Basic)	7.49	ChemAxon
Physiological Charge	1	ChemAxon
Hydrogen Acceptor Count	5	ChemAxon
Hydrogen Donor Count	2	ChemAxon
Polar Surface Area	62.2 Å2	ChemAxon
Rotatable Bond Count	1	ChemAxon
Refractivity	64.77 m3·mol-1	ChemAxon
Polarizability	23.97 Å3	ChemAxon
Number of Rings	3	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	1.0
Blood Brain Barrier	+	0.8592
Caco-2 permeable	+	0.5323
P-glycoprotein substrate	Substrate	0.6545
P-glycoprotein inhibitor I	Non-inhibitor	0.8365
P-glycoprotein inhibitor II	Non-inhibitor	0.7953
Renal organic cation transporter	Inhibitor	0.6577
CYP450 2C9 substrate	Non-substrate	0.7953
CYP450 2D6 substrate	Non-substrate	0.8018
CYP450 3A4 substrate	Non-substrate	0.5795
CYP450 1A2 substrate	Non-inhibitor	0.5248
CYP450 2C9 inhibitor	Non-inhibitor	0.7117
CYP450 2D6 inhibitor	Non-inhibitor	0.7867
CYP450 2C19 inhibitor	Non-inhibitor	0.6353
CYP450 3A4 inhibitor	Non-inhibitor	0.781
CYP450 inhibitory promiscuity	High CYP Inhibitory Promiscuity	0.5
Ames test	Non AMES toxic	0.6538
Carcinogenicity	Non-carcinogens	0.8915
Biodegradation	Not ready biodegradable	1.0
Rat acute toxicity	2.6573 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.6935
hERG inhibition (predictor II)	Non-inhibitor	0.8907

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	Not Available
Mass Spectrum (Electron Ionization)	MS	splash10-0udi-5490000000-5ee0610f321160b63c82
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available

Taxonomy

Description

This compound belongs to the class of organic compounds known as benzothiadiazoles. These are heterocyclic aromatic compounds containing a benzene ring fused to a thiadiazole ring. Thiadiazole is a five-membered aromatic heterocycle made up of one sulfur atom and two nitrogen atoms.

Kingdom

Organic compounds

Super Class

Organoheterocyclic compounds

Class

Benzothiadiazoles

Sub Class

Not Available

Direct Parent

Benzothiadiazoles

Alternative Parents

Benzenoids / Aryl chlorides / Thiadiazoles / Imidazolines / Heteroaromatic compounds / Guanidines / Propargyl-type 1,3-dipolar organic compounds / Carboximidamides / Azacyclic compounds / Organopnictogen compoundsOrganochlorides / Hydrocarbon derivatives

show 2 more

Substituents

2,1,3-benzothiadiazole / Aryl chloride / Aryl halide / Benzenoid / Azole / Heteroaromatic compound / 2-imidazoline / Thiadiazole / Guanidine / Propargyl-type 1,3-dipolar organic compoundOrganic 1,3-dipolar compound / Azacycle / Carboximidamide / Organonitrogen compound / Organochloride / Organohalogen compound / Hydrocarbon derivative / Organopnictogen compound / Organic nitrogen compound / Aromatic heteropolycyclic compound

show 10 more

Molecular Framework

Aromatic heteropolycyclic compounds

External Descriptors

imidazoles, benzothiadiazole (CHEBI:63629)

Drug created on June 13, 2005 07:24 / Updated on June 19, 2018 10:50